Phase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxBreaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer
/0 Comments/in Preclinical Research/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/0 Comments/in Post-hoc, Retrospective studies/by MaxNewsletter 11/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Tired of this rain! Today’s update highlights three promising clinical trials alongside two intriguing preclinical studies. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it […]
Phase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxEVM16: A Personalized mRNA Cancer Vaccine Enters Clinical Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNew Research Unlocks Potential for Immunotherapy in Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein September 2, 2025
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025